As the internet becomes flooded with AI-generated content, a peculiar set of challenges emerges. One challenge is to humans, with the now-familiar problem of information overload. A new challenge is to the AI models themselves, with the use of AI-generated content to train the models causing potential AI disorders.
The internet is beginning to fill up with more and more content generated by artificial intelligence rather than human beings, posing weird new dangers … The danger to AI itself is newer and stranger. A raft of recent research papers have introduced a novel lexicon of potential AI disorders that are just coming into view as the technology is more widely deployed and used.
View referenced article
Author(s)
Related Insights
July 21, 2026
Foley Viewpoints
Is Your Company IPO-Ready? The 12-Month Checklist
Traditional IPOs raised roughly $114 billion in the first half of 2026, more than seven times the total from the same period last year. Sixty-five companies went public, nearly double the prior year's count, and most opened above their offer price. Boards have noticed, and the question I hear most often now is whether the company is ready.
July 20, 2026
Foley Viewpoints
The Texas Business Court Issues Its First Published Opinion on a TCPA Motion to Dismiss
July 20, 2026
Practical Guidance for Pharmaceutical Method-of-Use Patent Claims After Teva v. Eli Lilly and In re Xencor
In our companion article, Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus, we analyzed two recent Federal Circuit decisions that offer complementary guidance on a recurring question in patent law: what must a patent specification disclose to satisfy written description and enablement under 35 U.S.C. § 112 when the claimed invention is the new use of a genus of known compounds or compositions?